Supplies of a promising drug for cancer, HIV and possibly other diseases is dwindling, and scientists have struggled to extract more from the marine creatures who produce it. Now, chemists have a synthetic solution.
A drug isolated from a marine pest holds promise for treating some of the world’s nastiest diseases, and researchers would love to find out just how effective it is – if only they could get their hands on more. As it stands, the world’s supply of the chemical is down to about half of what it was in the 1990s, and it is hard to extract in sufficient quantities from the feathery sea creatures that produce it.
Now, Stanford researchers have found a simpler and more efficient way to make this increasingly in-demand compound in the lab, they report October 6 in the journal Science. Their new synthetic supply will be enough to continue ongoing trials testing its effectiveness as a cancer immunotherapy and for treating Alzheimer’s disease and HIV, for which any further supply was until now uncertain.
Principal investigator Paul Wender, a professor of chemistry and member of Stanford ChEM-H, said he got so excited about the project at one point, “I put on my lab coat and did some crystallizations,” one of the basic steps of chemistry lab work usually left to students, not full professors. For him, the new paper is the result of decades of work and a happy accident in the Gulf of Mexico almost 50 years ago.
From three elephants to a salt shaker
Like many other naturally occurring chemicals put into service as pharmaceuticals, bryostatin was discovered following what was essentially a fishing expedition. In the 1960s, having had some success developing drugs from terrestrial flora and fauna, scientists began to shift attention to marine life.
The story of bryostatin itself began in 1968, when a marine biologist working in the Gulf of Mexico collected a plethora of marine organisms and sent them to the National Cancer Institute for analysis. One of those organisms, Bugula neritina, a pest best known for fouling up marine environments, showed some promise as an anti-cancer agent. A decade and a half later, researchers reported the structure of the active ingredient, which they dubbed bryostatin 1 after the animal’s common name, brown bryozoan.
Unfortunately, bryostatin 1 is very hard to come by. When NCI scientists went back and swept up 14 tons of B. neritina, they managed to extract just 18 grams of bryostatin.
“It’s basically three elephants going down to a salt shaker,” Wender said.
Worse, subsequent studies showed that B. neritina produces bryostatin only in depths greater than about 10 feet and in warmer seas closer to the equator, and only during certain times of the year. (In fact, the NCI’s 14-ton collection came from California, because subsequent samples from the Gulf of Mexico proved inactive.) And while there was a way to synthesize bryostatin in the lab, it took 57 steps and was not very efficient.
Improving on nature
Wender and his group have been working with bryostatin analogs – chemicals inspired by bryostatin, but not quite the same – since the 1980s but only recently began thinking about how to make bryostatin itself in a lab.
“Ordinarily, we’re in the business of making chemicals that are better than the natural products” such as bryostatin, Wender said. Wender and his lab’s job, in other words, is to come up with chemicals inspired by nature, but more effective.
“But when we started to realize that clinical trials a lot of people were thinking about were not being done because they didn’t have enough material, we decided, ‘That’s it, we’re going to roll up our sleeves and make bryostatin because it is now in demand,’” Wender said.
Dusting off the lab coat
After decades of experience with bryostatin analogs and two years of concerted effort, the lab came up with a much shorter, 29-step process and a yield of 4.8 percent, tens of thousands of times more efficient than extracting bryostatin from B. neritina, and substantially simpler and more efficient than the previous synthetic approach.
“The talent and dedication of this group made possible an achievement which many had thought impossible,” Wender said. “We are so fortunate to have people who are undeterred by that.”
The team members have now produced over 2 grams of bryostatin 1, and once production is scaled up, Wender said, they expect manufacturers could produce about 20 grams per year, enough to cover clinical and research needs. That is a bit more than was ever extracted from B. neritina and enough to treat about 20,000 cancer patients or 40,000 Alzheimer’s patients.
The results could also be a boon for HIV/AIDS research. In late September, the team reported that a bryostatin 1 analog could help wake latent HIV-infected cells, making them more susceptible to attack by HIV drugs or the immune system. With new insight into – and a new supply of – bryostatin 1, Wender said, “we have an opportunity to start in earnest a clinical conversation about eradicating HIV/AIDS.”
The Latest on: Bryostatin
- Neurotrope to Present Additional Phase 2 Data at the 11th Edition of Clinical Trials on Alzheimer's Disease (CTAD2018) on September 26, 2018 at 5:30 am
Details of the poster presentations are as follows: Title: Evidence of Sustained Low Dose Bryostatin Efficacy for Treatment of Alzheimer's Disease: Consistency of Multiple Evaluation Analyses Presenta... […]
- Neurotrope to Present Additional Phase 2 Data at the 11th Edition of Clinical Trials on Alzheimer's Disease (CTAD2018) on September 25, 2018 at 5:00 pm
If you are affiliated with this page and would like it removed please contact [email protected] SOURCE Neurotrope, Inc. "Leveraging decades of work on the PKC pathway at NIH and other leadi... […]
- Neurotrope begins patient enrollment in phase 2 trial of Alzheimer's disease drug, Bryostatin-1 on July 17, 2018 at 11:00 pm
Neurotrope Inc. a clinical-stage biopharmaceutical company, has announced that the first patient has been enrolled into its confirmatory phase 2 clinical trial with its lead Alzheimer's disease drug, ... […]
- Neurotrope Appoints Leading Experts in Alzheimer's Disease to its Scientific Advisory Board (SAB) on July 10, 2018 at 5:00 pm
"We believe that this team of accomplished leading academicians will enhance our company's ability to accelerate the development of bryostatin in Alzheimer's Disease and other neurological disorders, ... […]
- Researchers delve into deep blue sea for anti-cancer agents on July 9, 2018 at 10:44 am
One of these promising marine-based drugs – bryostatin – is offering some cancer patients new hope at the USC/Norris Comprehensive Cancer Center. The drug is derived from a strain of tiny, sponge-like ... […]
- Neurotrope And The Missing Step In Alzheimer's Disease on March 13, 2018 at 12:26 pm
Bryostatin-1 is potentially neuroprotective via its activation of the phoshatidylinositol 3-kinase/Akt pathway. This pathway is inhibited by nitration in Alzheimer's disease. Compounds that reverse th... […]
- BRIEF-Neurotrope's Bryostatin Improves Cognition In Patients on January 5, 2018 at 6:45 am
Jan 5 (Reuters) - Neurotrope Inc: * NEUROTROPE’S BRYOSTATIN IMPROVES COGNITION IN PATIENTS WITH ADVANCED ALZHEIMER’S DISEASE BASED ON FURTHER ANALYSIS OF PHASE 2 CLINICAL TRIAL DATA Source text for Ei... […]
- Neurotrope's Bryostatin Improves Cognition in Patients with Advanced Alzheimer's Disease Based on Further Analysis of Phase 2 Clinical Trial Data on January 4, 2018 at 4:00 pm
- Improvements in cognition found in advanced Alzheimer's disease patients receiving 20μg bryostatin in absence of background memantine therapy - - Sustained improvements in cognition observed 30 days ... […]
- Supplies of a Rare Cancer-Killing Compound Were Dwindling…Not Anymore on October 12, 2017 at 3:03 pm
You see, B. neritina is the natural source of bryostatins, and scientists had discovered that these compounds, namely bryostatin 1, could be potent weapons in the fight against cancer. In all, NCI har... […]
- Neurotrope to Present Bryostatin Phase 2 Data in an Oral Presentation at AAIC 2017 Meeting on June 29, 2017 at 6:33 am
NEW YORK, June 29, 2017 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP) today announced the acceptance of a late breaking oral presentation at the Alzheimer's Association International Conference 2017 ... […]
via Google News and Bing News